Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing-A multicentre study

被引:1
|
作者
Willixhofer, Robin [1 ]
Contini, Mauro [2 ]
Emdin, Michele [3 ,4 ]
Magri, Damiano [5 ]
Bonomi, Alice [2 ]
Salvioni, Elisabetta [2 ]
Celeste, Fabrizio [2 ]
Del Torto, Alberico [2 ]
Passino, Claudio [3 ,4 ]
Capelle, Christophe D. J. [1 ]
Arzilli, Chiara [3 ,4 ]
Fiori, Emiliano [5 ]
Capra, Nicolo [2 ]
Kronberger, Christina [1 ]
Ermolaev, Nikita [1 ]
Kammerlander, Andreas [1 ]
Musumeci, Beatrice [5 ]
Vergaro, Giuseppe [3 ,4 ]
Castiglione, Vincenzo [3 ,4 ]
Rettl, Rene [1 ]
Tini, Giacomo [5 ]
Baggiano, Andrea [2 ]
Fabiani, Iacopo [3 ,4 ]
Sciomer, Susanna [6 ]
Badr Eslam, Roza [1 ]
Agostoni, Piergiuseppe [2 ,7 ]
机构
[1] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Waehringer Guerte l18-20, A-1090 Vienna, Austria
[2] IRCCS, Ctr Cardiol Monzino, Milan, Italy
[3] Scuola Super Sant Anna, Hlth Sci Interdisciplinary Ctr, Pisa, Italy
[4] Fdn Toscana Gabriele Monasterio, Pisa, Italy
[5] Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Rome, Italy
[6] Sapienza Univ Rome, Dept Clin Internal Med Anestesiol & Cardiol Sci, Rome, Italy
[7] Univ Milan, Dept Clin Sci & Community Hlth, Cardiovasc Sect, Milan, Italy
来源
ESC HEART FAILURE | 2024年
关键词
functional capacity; heart failure; restrictive cardiomyopathy; transthyretin amyloidosis; light chain amyloidosis; HEART-FAILURE; ANAEROBIC THRESHOLD; EUROPEAN-SOCIETY; RISK;
D O I
10.1002/ehf2.15147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction. This study aimed to determine whether cardiac output reduction or ventilation inefficiency plays a predominant role in limiting exercise in patients with amyloid cardiomyopathy. Methods We conducted a multicentre prospective study in patients with AL or ATTR cardiomyopathy who underwent cardiopulmonary exercise testing across four centres. Patients were compared with a propensity-score matched HF cohort based on age, gender, left ventricular ejection fraction (LVEF), and peak oxygen consumption (VO2). Results Data from 267 amyloid patients aged 77 (72, 81) years, 86% male, with a median N-terminal pro B-type natriuretic peptide (NT-proBNP) of 2187 (1140, 4383) ng/L, exercise parameters of peak VO2 of 14.1 (11.6;16.9) mL/min/kg, a minute ventilation to carbon dioxide production (VE/VCO2) slope of 37.4 (32.5, 42.6) and a LVEF of 50% (44%, 59%) were analysed. We identified 251 amyloid cardiomyopathy-HF matches. Amyloid patients had a signifnicantly higher VE/VCO2 slope [37.4, inter quartile range (IQR): 32.7, 43.1 vs. 32.1, IQR: 28.7, 37.0, P < 0.0001], NT-proBNP (2249, IQR: 1187, 4420 vs. 718, IQR: 405, 2161 ng/L, P < 0.001), peak heart rate (121 +/- 28 vs. 115 +/- 27 beats/min, P = 0.007) and peak ventilation (51, IQR: 42, 62 vs. 43, IQR: 33, 53 L/min, P < 0.0001) with earlier anaerobic threshold (VO2 at AT: 8.9, IQR: 6.8, 10.8 vs. 10.8, IQR: 8.9, 12.7 mL/min/kg, P < 0.0001) compared with HF. Between amyloid patients, AL patients (n = 27) were younger (63, IQR: 58, 70 vs. 78, IQR: 72, 81 years, P < 0.0001), had lower VE/VCO2 slope (35.0, IQR: 30.0, 38.7 vs. 38.0, IQR: 32.8, 43.1, P = 0.019), higher end-tidal carbon dioxide partial pressure both at AT (35.1 +/- 4.8 vs. 31.4 +/- 4.7 mmHg, P < 0.001) and peak exercise (32, IQR: 28, 35 vs. 30, IQR: 26, 33 mmHg, P = 0.039) as compared with ATTR (n = 233). Conclusions A higher VE/VCO2 slope and an earlier AT, determining functional capacity impairment, was assessed in patients with amyloid cardiomyopathy compared with the matched HF cohort. Additionally, patients with ATTR might display more severe exercise limitations as compared with AL.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Exercise oxygen kinetic in hypertrophic cardiomyopathy: results from a multicentre cardiopulmonary exercise testing study
    Mapelli, Massimo
    Romani, Simona
    Magri, Damiano
    Merlo, Marco
    Cittar, Marco
    Prime, Marco Mase
    Muratori, Manuela
    Gallo, Giovanna
    Sclafani, Matteo
    Carriere, Cosimo
    Zaffalon, Denise
    Salvioni, Elisabetta
    Mattavelli, Irene
    Vignati, Carlo
    De Martino, Fabiana
    Rovai, Sara
    Autore, Camillo
    Sinagra, Gianfranco
    Agostoni, Piergiuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
  • [2] Exercise oxygen kinetic in hypertrophic cardiomyopathy: results from a multicentre cardiopulmonary exercise testing study
    Mapelli, Massimo
    Romani, Simona
    Magri, Damiano
    Merlo, Marco
    Cittar, Marco
    Mase, Marco
    Muratori, Manuela
    Gallo, Giovanna
    Sclafani, Matteo
    Carriere, Cosimo
    Zaffalon, Denise
    Salvioni, Elisabetta
    Mattavelli, Irene
    Vignati, Carlo
    De Martino, Fabiana
    Rovai, Sara
    Autore, Camillo
    Sinagra, Gianfranco
    Agostoni, Piergiuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
  • [3] Cardiopulmonary Exercise Testing in Athletes With Hypertrophic Cardiomyopathy
    Newman, Darrell B.
    Garmany, Ramin
    Contreras, Alejandra Meza
    Bos, J. Martijn
    Johnson, Jonathan N.
    Geske, Jeffrey B.
    Allison, Thomas G.
    Ommen, Steve R.
    Ackerman, Michael J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 189 : 49 - 55
  • [4] Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy
    Coats, Caroline J.
    Rantell, Khadija
    Bartnik, Aleksandra
    Patel, Amour
    Mist, Bryan
    McKenna, William J.
    Elliott, Perry M.
    CIRCULATION-HEART FAILURE, 2015, 8 (06) : 1022 - 1031
  • [5] The Role of Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy
    Mikic, Lidija
    Ristic, Arsen
    Nikolic, Natasa Markovic
    Tesic, Milorad
    Jakovljevic, Djordje G.
    Arena, Ross
    Allison, Thomas G.
    Popovic, Dejana
    MEDICINA-LITHUANIA, 2023, 59 (07):
  • [6] Cardiopulmonary Exercise Testing in Athletes With Hypertrophic Cardiomyopathy
    Newman, Darrell B.
    Garmany, Ramin
    Contreras, Alejandra Meza
    Bos, J. Martijn
    Johnson, Jonathan N.
    Geske, Jeffrey B.
    Allison, Thomas G.
    Ommen, Steve R.
    Ackerman, Michael J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 189 : 49 - 55
  • [7] CARDIOPULMONARY EXERCISE TESTING AND PROGNOSIS IN HYPERTROPHIC CARDIOMYOPATHY
    Coats, Caroline
    Rantell, Khadija
    Bartnik, Ola
    Patel, Amour
    Mist, Bryan
    McKenna, William
    Elliott, Perry
    HEART, 2014, 100 : A50 - A51
  • [8] Identifying limitations to exercise with incremental cardiopulmonary exercise testing: a scoping review
    Staes, Michael
    Gyselinck, Iwein
    Goetschalckx, Kaatje
    Troosters, Thierry
    Janssens, Wim
    EUROPEAN RESPIRATORY REVIEW, 2024, 33 (173):
  • [9] Exercise oxygen kinetic in hypertrophic cardiomyopathy: results from a multicenter cardiopulmonary exercise testing study
    Mapelli, M. Massimo
    Romani, S.
    Magri, D.
    Merlo, M.
    Cittar, M.
    Muratori, M.
    Gallo, G.
    Sclafani, M.
    Carriere, C.
    Mase, M.
    Zaffalon, D.
    Salvioni, E.
    Autore, C.
    Sinagra, G.
    Agostoni, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 221 - 221
  • [10] EXERCISE OXYGEN KINETIC IN HYPERTROPHIC CARDIOMYOPATHY: RESULTS FROM A MULTICENTER CARDIOPULMONARY EXERCISE TESTING STUDY
    Mapelli, M.
    Romani, S.
    Magri, D.
    Merlo, M.
    Cittar, M.
    Mase, M.
    Muratori, M.
    Gallo, G.
    Sclafani, M.
    Carriere, C.
    Zaffalon, D.
    Salvioni, E.
    Mattavelli, I.
    Vignati, C.
    De Martino, F.
    Rovai, S.
    Autore, C.
    Sinagra, G.
    Agostoni, P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)